Mary Ann Anderson

15PUBLICATIONS
89CO-AUTHORS
Language documentation and descriptionGenomicsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 07, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

|Jun 18, 2026
Frontline CLL: lessons from the final analysis of CLL13-GAIA.

|Mar 17, 2026
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.

Mathias Castonguay, Mary Ann Anderson, Philip A Thompson

|Jul 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Stephen P Mulligan, Philip A Thompson, Joel Wight

|Jul 27, 2025
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.

Mary Ann Anderson, Farrukh T Awan, Leanne Berkahn

|Oct 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.

Meng-Xiao Luo, Tania Tan, Marie Trussart

Pageof 3

Frequent Collaborators

5 joint publications

Constantine Tam

4 joint publications

John Francis Seymour

3 joint publications

Tara Cochrane

3 joint publications

Andrew W Roberts